{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-23-000039","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.625175+00:00","generated_at":"2026-06-08T13:59:18.587827+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Xencor receives $215M royalty payment, Q3 net loss $(0.40)/share; cash runway into 2027","bullets":["Royalty transaction with OMERS yields $215M upfront for portions of Ultomiris and Monjuvi royalties; cash runway extended to 2027.","Q3 revenue $59.2M, net loss $24.3M ($0.40 EPS) vs net loss $32.8M ($0.55 EPS) in Q3 2022.","Discontinued XmAb104 (PD-1 x ICOS) after Phase 1 expansion missed efficacy criteria; narrowed vudalimab enrollment.","Converted Genentech IL-15 co-development to milestone/royalty; plans to file IND for CLDN6 x CD3 (XmAb541) by year-end.","CFO John Kuch to retire March 2024; search for replacement initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-23-000039","json":"https://secwatch.observer/filing/0001326732-23-000039.json","markdown":"https://secwatch.observer/filing/0001326732-23-000039.md","text":"https://secwatch.observer/filing/0001326732-23-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673223000039/0001326732-23-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673223000039/xncr-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T13:59:18.587827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cac2388f5d13cf8c74c369bea9e256c97a5182d6","claim":"Xencor Inc reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 7, 2023, Xencor, Inc. announced its financial results for the third quarter ended September 30, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326732/000132673223000039/0001326732-23-000039-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}